Boehringer bags Jardiance NICE nod
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim has won NICE's recommendation in draft guidance for its type 2 diabetes drug Jardiance (empagliflozin), but the company, which is third to the UK market, may find gaining market share tough.